Pharming Group FY2026 EPS Estimate Boosted by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – HC Wainwright raised their FY2026 earnings per share estimates for Pharming Group in a note issued to investors on Thursday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.67 for the year, up from their prior estimate of $0.60. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s FY2027 earnings at $1.06 EPS.

A number of other analysts have also weighed in on the stock. Zacks Research lowered shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. Weiss Ratings upgraded Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Pharming Group has an average rating of “Moderate Buy” and an average target price of $30.00.

Pharming Group Stock Up 5.0%

Shares of NASDAQ PHAR opened at $15.43 on Friday. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -1,541.46 and a beta of 0.03. Pharming Group has a 52 week low of $7.31 and a 52 week high of $17.08. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The firm’s fifty day moving average is $14.30 and its 200 day moving average is $12.01.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.05. Pharming Group had a return on equity of 0.48% and a net margin of 0.30%.The company had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group has set its FY 2025 guidance at EPS.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.